SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc. (NASDAQ:ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the
Financing will support Star’s next phase of growth, including advancement of current preclinical programs into the clinic and continued pipeline expansion
Financing follows Incyte’s July 2026 acquisition of Star
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment
